Aerpio Pharmaceuticals, Inc. (ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.
The presentation will be webcast live and may be accessed by visiting Aerpio's website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class compounds that activate Tie2 to treat ocular diseases and complications of diabetes. Tie2 is an important regulator of vascular stability and its down-regulation is found in patients with diabetes and other conditions. Down-regulation is caused by activation of two inhibitors of Tie2, VE-PTP and Ang-2. The Company’s lead compound, AKB-9778, is being investigated for its potential utility in treating diabetic nephropathy and an eyedrop formulation is in development as a potential treatment for open-angle glaucoma. For more information, please visit www.aerpio.com